Rosetta Genomics Ltd. (ROSG) At $0.42 Forms Bottom; Last Week Inovalon Holdings, Inc. (INOV) Analysts

Rosetta Genomics Ltd. (NASDAQ:ROSG) Logo

Rosetta Genomics Ltd. (ROSG) formed multiple bottom with $0.39 target or 9.00% below today’s $0.42 share price. Rosetta Genomics Ltd. (ROSG) has $2.51M valuation. The stock decreased 0.05% or $0.0002 during the last trading session, reaching $0.4233. About 4,679 shares traded. Rosetta Genomics Ltd. (NASDAQ:ROSG) has declined 87.46% since May 11, 2017 and is downtrending. It has underperformed by 99.01% the S&P500.

Among 11 analysts covering Inovalon Holdings Inc (NASDAQ:INOV), 1 have Buy rating, 3 Sell and 7 Hold. Therefore 9% are positive. Inovalon Holdings Inc had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Inovalon Holdings, Inc. (NASDAQ:INOV) earned “Neutral” rating by Goldman Sachs on Thursday, August 4. Wells Fargo maintained Inovalon Holdings, Inc. (NASDAQ:INOV) on Wednesday, February 21 with “Market Perform” rating. William Blair downgraded Inovalon Holdings, Inc. (NASDAQ:INOV) on Thursday, August 4 to “Market Perform” rating. Robert W. Baird maintained Inovalon Holdings, Inc. (NASDAQ:INOV) rating on Tuesday, September 12. Robert W. Baird has “Hold” rating and $13.0 target. The rating was downgraded by Morgan Stanley on Wednesday, March 30 to “Underweight”. As per Tuesday, August 16, the company rating was maintained by KeyBanc Capital Markets. The firm has “Hold” rating by Zacks given on Monday, August 10. Morgan Stanley downgraded the stock to “Underweight” rating in Wednesday, March 14 report. As per Thursday, August 4, the company rating was maintained by Citigroup. As per Tuesday, August 25, the company rating was maintained by William Blair. See Inovalon Holdings, Inc. (NASDAQ:INOV) latest ratings:

14/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Underweight Old Target: $14 Downgrade
21/02/2018 Broker: Piper Jaffray Rating: Sell New Target: $8.0 Maintain
21/02/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $16 New Target: $14 Maintain

The stock increased 1.62% or $0.15 during the last trading session, reaching $9.425. About 216,662 shares traded. Inovalon Holdings, Inc. (NASDAQ:INOV) has declined 14.88% since May 11, 2017 and is downtrending. It has underperformed by 26.43% the S&P500.

Inovalon Holdings, Inc., a technology company, provides cloud platforms empowering a data-driven transformation from volume to value models throughout the healthcare industry. The company has market cap of $1.44 billion. The firm through, large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and industry-leading subject matter expertise, enables the assessment and improvement of clinical and quality outcomes, and financial performance across the healthcare ecosystem. It has a 39.6 P/E ratio. It serves health plans and well-known provider organizations, as well as pharmaceutical, medical device, and diagnostics companies.

More notable recent Inovalon Holdings, Inc. (NASDAQ:INOV) news were published by: Globenewswire.com which released: “Inovalon Reports First Quarter 2018 Results” on May 08, 2018, also Seekingalpha.com with their article: “Inovalon’s (INOV) CEO Keith Dunleavy on Q1 2018 Results – Earnings Call Transcript” published on May 09, 2018, Globenewswire.com published: “Inovalon Announces First Quarter 2018 Earnings Conference Call” on April 25, 2018. More interesting news about Inovalon Holdings, Inc. (NASDAQ:INOV) were released by: Benzinga.com and their article: “54 Biggest Movers From Yesterday” published on May 10, 2018 as well as Nasdaq.com‘s news article titled: “Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties …” with publication date: May 01, 2018.

Among 2 analysts covering Rosetta Genomics (NASDAQ:ROSG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Rosetta Genomics had 2 analyst reports since December 18, 2015 according to SRatingsIntel. The stock of Rosetta Genomics Ltd. (NASDAQ:ROSG) has “Market Perform” rating given on Monday, December 18 by Barrington Research. Cantor Fitzgerald initiated the shares of ROSG in report on Friday, December 18 with “Buy” rating.

Inovalon Holdings, Inc. (NASDAQ:INOV) Ratings Chart